Seeking Alpha
  • Michael Hagan
    A product which may effectively compete with Cynapsus is Civitas' CVT 301 which announced a successful phase 2b trial April 28th. $CYNAF
    6/2/14
    Reply (3)
    • Len Friedman: Can you furnish the ticker so I can commence dd? Thanks.
      6/2/14
    • Michael Hagan: Private investors at this point
      6/3/14
    • Len Friedman: I'm thinking a reverse merger may be the only route for your find. That could tie things up long enough for CYNAF to saturate the market.
      6/8/14